Friday, October 24, 2014 9:43:24 PM
For ABSSSI, the calculation should go like this;
18 million patients a year for ABSSSI, 15% initial market penetration = 2.7 million treatments per year @ $2500 per course (current median for MSRA treatments) = $6.75 billion/year with year over year increases.
The rest calculations including "5 times" stock market valuation are correct. So the final valuation number for Brilacidin should be, 6.75+0.35+1.3=$8.4 billions.
<<
18 million patients a year for ABSSSI, 15% initial market penetration = 2.7 million treatments per year @ $2500 per course (current median for MSRA treatments) = $675 million/year with year over year increases.
B-OM has no effective treatment for 400K cases per year so 25% market penetration = 100K cases @ $3,500 per treatment = $350 million and increasing year over year.
B-Diabetic foot has 3.5 million cases a year so 15% market penetration is 520K per year @ 2500 per treatment = 1.3 billion with year over year increases.
Brilacidin for 3 indications all entering Phase 2/3 or 3 trials in the next 6 months has an initial market potential of $2.325 billion in annual sales. So, expected cap would be 5 times that. Oh, did I mention these are minimums?
Thanks, I just packed my nose with cotton to stop another nose bleed. And, those numbers weren't even crazy high yet.
>>
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM